ロード中...

Lutetium Lu-177 Dotatate Flare Reaction

PURPOSE: Lutetium Lu-177 dotatate is the first peptide receptor radionuclide therapy approved by the US Food and Drug Administration. Well-designed studies in Europe have shown dramatic effectiveness in improving progression-free survival in patients with gastroenteropancreatic neuroendocrine tumors...

詳細記述

保存先:
書誌詳細
出版年:Adv Radiat Oncol
主要な著者: Salner, Andrew L., Blankenship, Bette, Dunnack, Hayley, Niemann, Christopher, Bertsch, Helaine
フォーマット: Artigo
言語:Inglês
出版事項: Elsevier 2020
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7811111/
https://ncbi.nlm.nih.gov/pubmed/33490736
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.adro.2020.11.008
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!